Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research
Neuroplastogen biotech company Enveric Biosciences (NASDAQ:ENVB) has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression.
EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate.
The move follows the company’s July announcement of positive pre-clinical results of its EB-003 drug candidate to be delivered via oral administration. The results indicated that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.
The presentation titled, “Non-hallucinogenic and neuropathogenic DMT analog imparts positive behavioral outcomes in mice,” addresses the criteria researchers evaluated in the design and development of EB-003 as …